Peroxisome proliferator-activated receptor β/δ as a therapeutic target for metabolic diseases

Author： Bedu Elodie Wahli Walter Desvergne Béatrice

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.9, Iss.4, 2005-08, pp. : 861-873

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Peroxisome Proliferator-Activated Receptor (PPAR)&bgr; /&dgr;: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome

Current Molecular Pharmacology, Vol. 2, Iss. 1, 2009-01 ,pp. : 46-55

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome proliferator-activated receptor-γ: therapeutic target for diseases beyond diabetes: quo vadis?

By Pershadsingh Harrihar A

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 3, 2004-03 ,pp. : 215-228

Informa Healthcare

Access to resources Recommend Favorite

Peroxisome proliferator-activated receptor-β as a target for wound healing drugs

By Tan Nguan Soon Michalik Liliane Desvergne Béatrice Wahli Walter

Expert Opinion on Therapeutic Targets, Vol. 8, Iss. 1, 2004-02 ,pp. : 39-48

Informa Healthcare

Access to resources Recommend Favorite

A selective peroxisome proliferator-activated receptor-β/δ agonist attenuates neointimal hyperplasia after wire-mediated arterial injury

By Hamaya Rikuta

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 9, 2013-09 ,pp. : 1095-1106

Informa Healthcare

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR)-α: A Pharmacological Target with a Promising Future

By van Raalte Daniel H. Li Min Pritchard P. Haydn Wasan Kishor M.

Pharmaceutical Research, Vol. 21, Iss. 9, 2004-09 ,pp. : 1531-1538

Springer Publishing Company

Access to resources Recommend Favorite